IMTELLIG Trademark

Trademark Overview

On Tuesday, April 20, 2021, a trademark application was filed for IMTELLIG with the United States Patent and Trademark Office. The USPTO has given the IMTELLIG trademark a serial number of 90658699. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Sunday, August 18, 2024. This trademark is owned by Geron Corporation. The IMTELLIG trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceuticals for the treatment, diagnosis or prophylaxis of human diseases, disorders and conditions, namely, cancer, and diseases, disorders and conditions of the hematological systems
imtellig

General Information

Serial Number90658699
Word MarkIMTELLIG
Filing DateTuesday, April 20, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateSunday, August 18, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 19, 2022

Trademark Statements

Goods and Servicespharmaceuticals for the treatment, diagnosis or prophylaxis of human diseases, disorders and conditions, namely, cancer, and diseases, disorders and conditions of the hematological systems

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, July 28, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGeron Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressFoster City, CA 94404
Party NameGeron Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressFoster City, CA 94404

Trademark Events

Event DateEvent Description
Friday, April 23, 2021NEW APPLICATION ENTERED
Wednesday, July 28, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 13, 2021ASSIGNED TO EXAMINER
Monday, December 13, 2021NON-FINAL ACTION E-MAILED
Monday, December 13, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, December 13, 2021NON-FINAL ACTION WRITTEN
Friday, June 10, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, June 10, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, June 10, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, June 16, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 29, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 19, 2022PUBLISHED FOR OPPOSITION
Tuesday, July 19, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, February 15, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, September 13, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, February 15, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, February 15, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, March 7, 2023SOU EXTENSION 1 FILED
Tuesday, March 7, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, March 7, 2023SOU EXTENSION 1 GRANTED
Tuesday, August 8, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, August 8, 2023SOU EXTENSION 2 FILED
Tuesday, August 8, 2023SOU EXTENSION 2 GRANTED
Thursday, March 9, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 6, 2024SOU EXTENSION 3 GRANTED
Thursday, August 10, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 6, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, February 6, 2024SOU EXTENSION 3 FILED
Thursday, February 8, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sunday, August 18, 2024SOU TEAS EXTENSION RECEIVED
Sunday, August 18, 2024SOU EXTENSION 4 FILED
Sunday, August 18, 2024SOU EXTENSION 4 GRANTED

Related Keywords

imtellig conditions disorders diseases cancer hematological systems namely treatment human pharmaceuticals